First-Line Therapy—Has the Standard of Care Shifted for Good?
In this episode, Dr. Sara Tolaney, of Dana-Farber Cancer Institute, discusses how DESTINY-Breast09 is redefining first-line treatment in HER2-positive metastatic breast cancer. She explores whether T-DXd plus pertuzumab should replace the long-standing THP regimen, the future role of induction-maintenance strategies, and open questions on optimal therapy duration.
Let us know what you thought of this week’s episode on Twitter: @physicianswkly
Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at [email protected]!
Thanks for listening!